View Categories

Acute Coronary Syndrome (ACS)

25 min read

Background #

Acute Coronary Syndrome (ACS) refers to a spectrum of conditions caused by acute myocardial ischemia due to plaque rupture, thrombosis, and coronary artery obstruction. It encompasses:

  • Unstable Angina (UA)
  • Non-ST-Elevation Myocardial Infarction (NSTEMI)
  • ST-Elevation Myocardial Infarction (STEMI)

These entities differ primarily in ECG findings and biomarker elevation but share similar pathophysiology and treatment pathways. [1]

Classification/Types

Acute Coronary Syndrome is classified based on ECG findings and cardiac biomarker elevation, which reflect the extent and duration of myocardial ischemia: [1]

1. Unstable Angina (UA)

  • Definition: Acute myocardial ischemia without myocardial necrosis
  • ECG: Normal, or ST-segment depression, T-wave inversion, or nonspecific changes
  • Biomarkers: Normal troponin and CK-MB (no myocyte death)
  • Clinical: Angina at rest, new-onset severe angina, or crescendo pattern (increasing frequency/severity)

2. Non-ST-Elevation Myocardial Infarction (NSTEMI)

  • Definition: Myocardial necrosis without ST-segment elevation
  • ECG: ST-segment depression, T-wave inversion, or nonspecific changes (no ST elevation)
  • Biomarkers: Elevated troponin and/or CK-MB
  • Pathology: Subendocardial (partial-thickness) infarction due to incomplete or intermittent occlusion

3. ST-Elevation Myocardial Infarction (STEMI)

  • Definition: Transmural myocardial infarction with complete coronary occlusion
  • ECG: ST-segment elevation ≥1 mm in ≥2 contiguous leads; may evolve to Q waves
  • Biomarkers: Markedly elevated troponin and CK-MB
  • Pathology: Full-thickness (transmural) myocardial necrosis
  • Urgency: Requires immediate reperfusion therapy (PCI or thrombolytics)

Epidemiology

Incidence and Prevalence

  • ACS accounts for approximately 1.5 million hospitalizations annually in the United States
  • STEMI represents roughly 25-40% of ACS cases; NSTEMI/UA comprise 60-75%
  • The incidence of STEMI has decreased over recent decades due to improved primary prevention and risk factor modification, while NSTEMI rates have increased, likely due to better detection with high-sensitivity troponin assays and an aging population

Mortality

  • In-hospital mortality: STEMI (~5-6%), NSTEMI (~3-5%), though NSTEMI has higher long-term mortality due to greater comorbidity burden
  • 30-day mortality: Approximately 10% for STEMI with timely intervention
  • Mortality has significantly declined with advances in reperfusion therapy, antiplatelet agents, and guideline-directed medical therapy [1]

Demographics

  • Age: Risk increases sharply after age 45 in men and age 55 in women (post-menopause)
  • Sex: Men have higher incidence at younger ages; risk equalizes in women after menopause due to loss of estrogen’s cardioprotective effects
  • Race/Ethnicity: African Americans have higher rates of hypertension and diabetes, leading to increased ACS risk; South Asians have disproportionately high rates of premature CAD

Geographic Variation

  • Higher rates in developed countries, though rising in developing nations due to adoption of Western lifestyles (diet, smoking, sedentary behavior)

Pathophysiology

Acute Coronary Syndrome (ACS) is initiated by rupture or erosion of an atherosclerotic plaque within a coronary artery. This rupture is triggered by factors such as hemodynamic stress, inflammation, or thinning of the fibrous cap overlying the plaque.

Once the plaque ruptures, the subendothelial collagen and tissue factor are exposed to circulating blood. This exposure activates platelets, which adhere to the damaged vessel wall and aggregate, forming the initial platelet plug. Simultaneously, the coagulation cascade is triggered, leading to thrombin generation and conversion of fibrinogen to fibrin, which stabilizes the thrombus.

The degree of coronary occlusion determines the clinical presentation:

  • Partial or transient occlusion (Unstable Angina & NSTEMI): The thrombus partially obstructs blood flow, causing inadequate oxygen delivery during increased myocardial demand. Collateral circulation may provide some compensation. In NSTEMI, prolonged ischemia leads to myocyte necrosis detectable by biomarker elevation.
  • Complete occlusion (STEMI): The thrombus completely blocks the coronary artery, resulting in transmural (full-thickness) myocardial infarction. Without prompt reperfusion, irreversible myocardial cell death occurs within 20-40 minutes, progressing in a “wavefront” pattern from endocardium to epicardium.

Ischemia disrupts cellular metabolism: Oxygen deprivation forces myocytes to shift from aerobic to anaerobic metabolism, producing lactic acid and causing intracellular acidosis. ATP depletion impairs ion pumps, leading to cellular swelling, membrane instability, and arrhythmias. If prolonged, this culminates in irreversible injury and necrosis. [1]

Etiology #

ACS results from an imbalance between myocardial oxygen supply and demand, most commonly due to:

Primary Cause: Atherosclerotic Plaque Rupture/Erosion (~90% of cases)

  • Atherosclerosis: Chronic accumulation of lipids, inflammatory cells, and fibrous tissue in coronary artery walls
  • Vulnerable plaque characteristics: Thin fibrous cap, large lipid-rich necrotic core, active inflammation (macrophages, T cells)
  • Triggers of rupture: Hemodynamic stress (hypertension, exercise), inflammation, increased sympathetic tone, circadian variation (peak incidence in early morning)
  • Thrombosis: Plaque rupture → platelet activation → thrombus formation → coronary occlusion

Secondary Causes (Type 2 MI – Supply-Demand Mismatch)

These cause myocardial injury without primary plaque rupture:

  • Coronary artery spasm (Prinzmetal’s angina): Vasospasm causing transient occlusion; often cocaine-induced
  • Coronary embolism: From left atrial thrombus (atrial fibrillation), endocarditis, or paradoxical embolism
  • Coronary dissection: Spontaneous coronary artery dissection (SCAD), especially in young women peripartum
  • Severe anemia: Reduced oxygen-carrying capacity
  • Hypotension/shock: Systemic hypoperfusion reducing coronary flow
  • Hypertensive emergency: Extreme afterload increasing oxygen demand
  • Tachyarrhythmias: Rapid heart rate increasing demand and decreasing diastolic filling time
  • Severe hypoxemia: Respiratory failure, carbon monoxide poisoning

Risk Factors (Predisposing Conditions)

Non-modifiable:

  • Advanced age (men >45, women >55)
  • Male sex
  • Family history of premature CAD (first-degree relative: men <55, women <65)
  • Genetic predisposition

Modifiable:

  • Smoking: Most potent modifiable risk factor; promotes endothelial dysfunction, inflammation, thrombosis
  • Hypertension: Chronic endothelial injury and increased afterload
  • Diabetes mellitus: Accelerated atherosclerosis, endothelial dysfunction
  • Dyslipidemia: Elevated LDL, low HDL, hypertriglyceridemia
  • Obesity: Particularly central/visceral adiposity
  • Sedentary lifestyle: Lack of cardiovascular conditioning
  • Chronic kidney disease: Accelerated vascular calcification and inflammation
  • Obstructive sleep apnea: Intermittent hypoxia, hypertension
  • Psychosocial stress: Chronic stress, depression

Emerging Risk Factors:

  • Elevated high-sensitivity C-reactive protein (hsCRP) – marker of inflammation
  • Elevated lipoprotein(a)
  • Hyperhomocysteinemia

Clinical Presentation #

History (Symptoms)

  • Chest pain (angina) described as pressure, tightness, or heaviness in the retrosternal area
  • May radiate to the left arm, neck, jaw, or back; usually lasts >20 minutes
  • Pain often not relieved by rest or sublingual nitroglycerin in ACS (especially NSTEMI/STEMI)
  • Associated symptoms: dyspnea, nausea, vomiting, diaphoresis, palpitations, lightheadedness
  • Atypical presentations (elderly, diabetics, women): dyspnea without pain, epigastric discomfort, or fatigue

Physical Exam (Signs)

Vital Signs:

  • Heart rate: Tachycardia due to sympathetic activation OR bradycardia in inferior wall MI (due to vagal stimulation or AV block)
  • Blood pressure: May be hypertensive (due to pain/stress or history of hypertension) OR hypotensive in cardiogenic shock or right ventricular (RV) infarct
  • Oxygen saturation: May be decreased in extensive myocardial infarction (MI) or pulmonary congestion
  • Temperature: Usually normal but can rise in late post-infarction stages due to inflammation

Focus Physical Exam:

Cardiovascular:

  • S3 gallop indicates left ventricular dysfunction
  • New murmurs, such as a holosystolic murmur at the apex, may suggest papillary muscle rupture (acute mitral regurgitation)
  • Irregular rhythms may point to arrhythmias like atrial fibrillation or premature ventricular contractions (PVCs)

Respiratory:

  • Bibasilar crackles may indicate pulmonary edema from left-sided heart failure
  • Tachypnea can be a compensatory response to hypoxia or acidosis

Peripheral Vascular:

  • Cool extremities, delayed capillary refill, and weak pulses may be signs of cardiogenic shock
  • Jugular venous distension (JVD) may be seen in RV infarction or biventricular failure

Neurological:

  • Altered mental status may occur due to hypoperfusion to the brain in shock states

Diagnostic Testing #

Initial Tests

12-lead ECG (immediately):

  • Best initial test to evaluate ACS
  • STEMI: ST elevations ≥1 mm in 2 or more contiguous leads
  • NSTEMI/UA: ST depressions, T-wave inversions, or nonspecific changes

MI Location, Artery Involved, and ECG Leads

MI LocationCoronary Artery InvolvedECG Leads with ST Elevation
AnteroseptalLeft Anterior Descending (LAD)V1–V2
AnteroapicalDistal LADV3–V4
Anterolateral WallLeft Circumflex (LCX) or LADV5–V6
LateralLCXI, aVL
Inferior WallRight Coronary Artery (RCA)II, III, aVF
Posterior WallPosterior Descending Artery (PDA)V7–V9 (posterior leads)
Right VentricleRCA (proximal)V4R (right-sided ECG)
Extensive AnteriorLeft Main or Proximal LADV1–V6, I, aVL

High-Sensitivity Cardiac Troponins

High-sensitivity cardiac troponin (hs-cTn) I or T is the preferred biomarker for detecting myocardial injury and distinguishing NSTEMI from UA:[2,3]

  • Elevated in STEMI and NSTEMI; normal in Unstable Angina
  • The 99th percentile upper reference limit is used as the diagnostic threshold for myocardial infarction
  • Serial testing (0/1-hour or 0/2-hour algorithms) can rapidly rule-in or rule-out acute MI with high sensitivity and specificity[3,4]
  • 0/1-hour algorithm: Optimized cut-offs for rule-out (e.g., Abbott <5 ng/L, Roche <5 ng/L) provide negative predictive value >99%[4]
  • 0/2-hour algorithm: Alternative for centers not using 0/1-hour protocols
  • Recheck every 1-3 hours based on clinical context and institutional protocol

Cardiac Enzymes in MI: Onset, Peak, and Duration

BiomarkerTime to RisePeakReturn to NormalClinical Notes
Troponin I/T3–6 hours12–24 hours7–10 days (I), 10–14 days (T)Most specific and sensitive for MI. Elevated longer — useful for late presentation.
CK-MB3–6 hours12–24 hours2–3 daysUseful for detecting reinfarction after initial MI due to shorter half-life.
Myoglobin1–2 hours6–9 hours24 hoursEarliest to rise, but least specific (also elevated in muscle injury).
LDH (LDH-1)12–24 hours2–3 days7–10 daysHistorically used; rarely used now due to poor specificity.

Basic Tests

  • CBC, CMP, lipid panel, glucose, coagulation panel
  • BNP if heart failure is suspected
  • ABG if hypoxia present
  • Urine drug screen in young patients with unclear etiology

Imaging

  • Coronary angiography: Most accurate test to diagnose CAD. Gold standard for evaluating coronary anatomy. Used to detect the anatomic location of coronary artery disease. Surgically correctable disease generally begins with 70% or greater stenosis.
  • Chest X-ray: Rule out pneumonia, aortic dissection, pneumothorax
  • Echocardiography: Evaluate wall motion abnormalities and ejection fraction. Decreased wall motion is seen in CAD. Ischemia causes reversible wall motion. Infarction is irreversible/fixed.

Differential Diagnosis of Chest Pain #

Cardiac

  • Pericarditis: Pleuritic pain, pericardial friction rub, diffuse ST elevation
  • Aortic dissection: Tearing pain radiating to back, pulse deficits
  • Heart failure exacerbation: Dyspnea, orthopnea, edema

Pulmonary

  • Pulmonary embolism: Sudden dyspnea, pleuritic chest pain, tachycardia
  • Pneumothorax: Unilateral decreased breath sounds, hyperresonance
  • Pneumonia: Fever, cough, focal consolidation

Gastrointestinal (GI)

  • GERD: Burning sensation, worsens when lying flat
  • Esophageal spasm: Mimics angina, unresponsive to nitroglycerin
  • Peptic ulcer disease: Epigastric pain, relief with antacids

Musculoskeletal (MSK)

  • Costochondritis: Reproducible chest wall tenderness
  • Muscle strain: Focal pain, history of exertion

Treatment #

The management of ACS has evolved significantly based on recent clinical trials and guidelines. The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes provides updated, evidence-based recommendations. [5]

Initial Stabilization and Symptom Relief

Oxygen Therapy

  • Indication: Only if SpO₂ <90% [5]
  • Not recommended routinely in normoxic patients (may increase mortality in some studies)

Pain Management

  • Morphine: For pain refractory to nitrates; use with caution as it may delay absorption of oral antiplatelet agents and has been associated with increased mortality in some observational studies [1,5]
  • Consider fentanyl as alternative analgesic

Nitroglycerin

  • Indication: Symptomatic relief of chest pain
  • Dose: Sublingual 0.4 mg every 5 minutes (up to 3 doses), then IV if persistent pain
  • Contraindications: [5]
    • Systolic BP <90 mmHg
    • Right ventricular infarction (inferior MI)
    • Recent use of phosphodiesterase-5 inhibitors (sildenafil within 24 hours, tadalafil within 48 hours)
    • Severe aortic stenosis

Antiplatelet Therapy

Aspirin

  • Dose: 162-325 mg PO (non-enteric coated, chewed for faster absorption) [5]
  • Mechanism: Irreversible COX-1 inhibition, reducing thromboxane A2 production
  • Mortality benefit: Well-established; cornerstone of ACS therapy
  • Long-term: 81 mg daily for indefinite duration

P2Y12 Inhibitors (Dual Antiplatelet Therapy – DAPT)

For STEMI or NSTEMI: [5,6]

Preferred agents (Class 1 recommendation – equal preference):

  • Ticagrelor: 180 mg loading dose, then 90 mg twice daily
    • Reversible P2Y12 inhibitor
    • No dose adjustment for weight or age
    • More dyspnea as side effect
  • Prasugrel: 60 mg loading dose, then 10 mg daily
    • Irreversible P2Y12 inhibitor
    • Contraindications: Prior stroke/TIA, age ≥75 years (relative), weight <60 kg (reduce to 5 mg)
    • Increased bleeding risk compared to clopidogrel

Alternative agent:

  • Clopidogrel: 600 mg loading dose, then 75 mg daily
    • Use if ticagrelor or prasugrel contraindicated, not tolerated, unaffordable, or unavailable
    • Prodrug requiring hepatic activation (CYP2C19)
    • Variable response due to genetic polymorphisms

Timing:[5]

  • For STEMI: Administer loading dose as soon as possible
  • For NSTEMI: Can defer until coronary anatomy defined if PCI planned within 24 hours
  • Pre-treatment before coronary angiography may be considered if delay >24 hours expected (Class 2b)

Intravenous option:

  • Cangrelor: May be reasonable in patients undergoing PCI who have not received oral P2Y12 inhibitor (Class 2b) [5]

DAPT Duration – Updated 2025 Guidelines

The duration of dual antiplatelet therapy has been refined based on recent evidence: [5,6,7]

Standard Duration:

  • Default: 12 months after ACS for patients without high bleeding risk (Class 1)
  • This applies to both STEMI and NSTEMI

Shortened DAPT (1-3 months): [6,7]

  • Selected patients may transition to P2Y12 inhibitor monotherapy after 1-3 months of DAPT
  • Consider based on:
    • High bleeding risk
    • Low ischemic risk
    • Patient preference
  • Ticagrelor monotherapy after 1 month has shown reduction in bleeding without increase in ischemic events in selected populations (Class 2b) [5]

Extended DAPT (>12 months):

  • May be considered in patients with high ischemic risk and low bleeding risk
  • Use validated risk scores (DAPT score, PRECISE-DAPT) to guide decision

Special Situations:

  • CABG: For patients who stop DAPT for CABG, resume DAPT postoperatively and continue for at least 12 months total (Class 1) [5]
  • Oral anticoagulation: For patients requiring OAC, abbreviated DAPT (1-4 weeks) followed by OAC plus antiplatelet monotherapy (preferentially clopidogrel) is recommended (Class 1) [5]

Important Note: De-escalation of antiplatelet therapy in the first 30 days after ACS is not recommended (Class 3) [1,7]

Anticoagulation

For PCI in STEMI: [5]

  • Unfractionated heparin (UFH): 70-100 units/kg bolus (max 10,000 units) – Class 1
  • Bivalirudin: Reduces mortality and bleeding compared to UFH (Class 1)
    • Consider high-dose post-PCI infusion

For NSTEMI: [5]

  • UFH: Weight-based dosing (60 units/kg bolus, max 4,000 units; infusion 12 units/kg/hr, max 1,000 units/hr) – Class 1
  • Enoxaparin (LMWH): 1 mg/kg subcutaneous twice daily – alternative to UFH
  • Bivalirudin: May be considered to reduce bleeding (Class 2b)
  • Fondaparinux: NOT recommended during PCI due to catheter thrombosis risk (Class 3) [5]

Beta-Blockers

Indications: [5]

  • Oral beta-blockers should be initiated within 24 hours in hemodynamically stable patients
  • Benefits: Reduce myocardial oxygen demand, decrease arrhythmias, reduce infarct size

Contraindications/Cautions:

  • Acute decompensated heart failure or pulmonary edema
  • Cardiogenic shock
  • Heart block (second or third degree without pacemaker)
  • Severe bradycardia (<50 bpm)
  • Hypotension (SBP <100 mmHg)
  • Reactive airway disease (relative)
  • Cocaine-associated MI (use with caution; may worsen coronary vasospasm)

Preferred agents:

  • Metoprolol tartrate: 25-50 mg PO twice daily initially
  • Carvedilol: 3.125 mg PO twice daily initially (has additional alpha-blocking properties)
  • Bisoprolol: 2.5-5 mg PO daily

ACE Inhibitors / ARBs

Indications: [5]

  • Initiate within 24 hours if:
    • EF ≤40%
    • Heart failure
    • Diabetes mellitus
    • Hypertension
    • Chronic kidney disease

Mortality benefit: Well-established, particularly in anterior MI and reduced EF

Preferred agents:

  • ACE inhibitors: Lisinopril 2.5-5 mg PO daily, ramipril 2.5 mg PO daily
  • ARBs: Valsartan 40 mg twice daily, losartan 25-50 mg daily (if ACE inhibitor not tolerated)

Contraindications:

  • Bilateral renal artery stenosis
  • Pregnancy
  • Angioedema history
  • Severe hypotension
  • Acute kidney injury

ARNI (Angiotensin Receptor-Neprilysin Inhibitor):

  • Sacubitril/valsartan: May be considered as alternative to ACE inhibitor/ARB in selected patients with HF and reduced EF (emerging evidence post-MI) [8]

Statins

High-intensity statin therapy: [5]

  • Initiate early (within 24 hours) regardless of baseline LDL cholesterol
  • Benefits: Plaque stabilization, anti-inflammatory effects, reduced recurrent events

Preferred agents:

  • Atorvastatin 40-80 mg PO daily
  • Rosuvastatin 20-40 mg PO daily

Goal: LDL-C <70 mg/dL (ideally <55 mg/dL in very high-risk patients per 2023 ESC guidelines) [1]

Additional lipid-lowering therapy: If LDL goals not met on maximally tolerated statin:

  • Ezetimibe: 10 mg daily
  • PCSK9 inhibitors: Evolocumab or alirocumab (for very high-risk patients or statin intolerance)
  • Bempedoic acid: Alternative for statin-intolerant patients

Aldosterone Antagonists

Indications:[5]

  • Post-MI patients with:
    • EF ≤40% AND
    • Heart failure symptoms OR diabetes mellitus

Agents:

  • Spironolactone: 25 mg daily
  • Eplerenone: 25 mg daily (more selective, fewer side effects)

Mortality benefit: Demonstrated in EPHESUS trial

Contraindications:

  • Serum creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women)
  • Serum potassium >5.0 mEq/L
  • Concomitant potassium-sparing diuretics

Monitoring: Recheck potassium and creatinine within 1 week, then monthly for 3 months

SGLT2 Inhibitors (Emerging Therapy)

Evidence: Recent trials demonstrate benefit in post-MI patients, particularly those with diabetes or heart failure:[9,10,11,12]

Indications:

  • Post-MI patients with:
    • Type 2 diabetes mellitus
    • Heart failure (HFrEF or HFpEF)
    • Chronic kidney disease

Agents:

  • Dapagliflozin: 10 mg daily
  • Empagliflozin: 10 mg daily

Benefits: [9,10,11,12]

  • Reduced heart failure hospitalization (RR 0.67-0.73)
  • Reduced MACE in selected populations
  • Improved ventricular remodeling
  • Reduced NT-proBNP levels

Timing: Initiation within 2-14 days post-MI appears safe and effective based on emerging data [11,12]

Contraindications:

  • Type 1 diabetes
  • Diabetic ketoacidosis
  • eGFR <20 mL/min/1.73m² (varies by agent)

Monitoring: Risk of euglycemic DKA (rare), genital mycotic infections, volume depletion

Colchicine (Anti-Inflammatory Therapy)

Evidence: COLCOT and LoDoCo2 trials demonstrated cardiovascular benefit: [13,14,15]

Indications: [13,14,15]

  • May be considered for secondary prevention in patients with chronic coronary disease or recent MI (Class 2b)
  • Most benefit seen when initiated 2-4 weeks post-MI (not immediately)

Dose: 0.5 mg once daily

Benefits:

  • 23-31% reduction in cardiovascular events
  • Reduced stroke (HR 0.26 in COLCOT)
  • Reduced urgent revascularization (HR 0.50 in COLCOT)
  • NO mortality benefit demonstrated

Contraindications:

  • Severe renal impairment (eGFR <30 mL/min)
  • Severe hepatic impairment
  • Concomitant use of strong CYP3A4 or P-glycoprotein inhibitors

Side effects: Diarrhea (most common), nausea, increased pneumonia risk

Important Note: NOT recommended for immediate treatment during acute phase of MI; benefit seen with delayed initiation (>2 weeks post-MI) [13,15]

Reperfusion Therapy (for STEMI)

Primary Percutaneous Coronary Intervention (PCI)

Gold standard for STEMI: [5]

  • Goal: Door-to-balloon time <90 minutes from first medical contact
  • Preferred over fibrinolysis when available in timely manner

Procedure:

  • Coronary angiography to identify culprit lesion
  • Balloon angioplasty ± stent placement
  • Aspiration thrombectomy NOT routinely recommended (Class 3) [5]

Drug-Eluting Stents (DES) preferred over Bare-Metal Stents (BMS):

  • Lower restenosis rates
  • Requires longer DAPT duration

Radial access preferred over femoral when operator experienced (reduces bleeding and vascular complications)

Complete revascularization: For STEMI with multivessel disease:

  • Treat culprit lesion immediately
  • Non-culprit lesions: Staged PCI during index hospitalization or shortly after (Class 2a) [5]

Fibrinolytic Therapy

Indications: [5]

  • STEMI patients when PCI unavailable within 120 minutes
  • Administer within 12 hours of symptom onset (ideally within 30 minutes of hospital arrival)

Agents:

  • Alteplase (tPA): 15 mg IV bolus, then 0.75 mg/kg over 30 min, then 0.5 mg/kg over 60 min
  • Reteplase (rPA): 10 units IV bolus × 2 doses, 30 minutes apart
  • Tenecteplase (TNK-tPA): Single weight-based IV bolus (preferred for ease of administration)

Absolute Contraindications:

  • Any prior intracranial hemorrhage
  • Known structural cerebrovascular lesion
  • Known malignant intracranial neoplasm
  • Ischemic stroke within 3 months
  • Suspected aortic dissection
  • Active bleeding or bleeding diathesis
  • Significant closed head trauma within 3 months
  • Intracranial or intraspinal surgery within 2 months

Relative Contraindications:

  • Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg)
  • History of ischemic stroke >3 months ago
  • Current anticoagulation therapy
  • Pregnancy
  • Recent internal bleeding (within 2-4 weeks)
  • For streptokinase: prior exposure (>5 days ago) or prior allergic reaction

Post-fibrinolysis management:

  • Transfer to PCI-capable facility for rescue PCI if failed reperfusion or routine angiography within 3-24 hours
  • Continue antiplatelet and anticoagulation therapy

Types of Stents in PCI #

Stent TypeDescriptionCommon UsesDAPT Duration
Bare-Metal Stent (BMS)Simple metal scaffold without drug coatingRarely used now; only when short DAPT needed (e.g., high bleeding risk, need for urgent surgery)Minimum 1 month
Drug-Eluting Stent (DES)Coated with antiproliferative drugs (e.g., sirolimus, everolimus, zotarolimus)First-line for most cases; significantly lowers restenosis risk6-12 months (ACS: 12 months)

Indications for Coronary Artery Bypass Graft (CABG) #

  • Left main coronary artery disease (≥50% stenosis)
  • Multi-vessel disease (especially in diabetics or reduced EF)
  • Failed PCI or complications
  • Severe proximal LAD stenosis with complex anatomy
  • Anatomically unsuitable for PCI (diffuse disease, chronic total occlusions)
  • STEMI with cardiogenic shock and multivessel disease (may benefit from CABG after stabilization)

Timing post-STEMI:

  • Ideally delayed 3-7 days when possible to allow for myocardial recovery
  • Emergency CABG for failed PCI or mechanical complications

Long-Term Treatment and Mortality-Reducing Therapies #

MedicationMortality BenefitNotes
AspirinYesLifelong; cornerstone of therapy
Beta-blockersYesDecrease myocardial oxygen demand, reduce arrhythmias; especially beneficial if EF <40%
ACE inhibitors / ARBsYesPrevent remodeling; especially in diabetics, HTN, or low EF
StatinsYesStabilize plaques, lower LDL; high-intensity preferred
Aldosterone antagonists (e.g., spironolactone, eplerenone)YesIn patients with EF ≤40% and HF or DM, after MI
DAPT (aspirin + P2Y12 inhibitor)YesContinue for 12 months post-MI/PCI (minimum); consider bleeding/ischemic risk for duration
SGLT2 inhibitors (in diabetes/HF)EmergingReduces HF hospitalization; mortality benefit in HF populations
ColchicineNo mortality benefitReduces cardiovascular events (23-31%); consider for secondary prevention

Post-MI Complications #

Immediate (0–24 hours)

1. Arrhythmias

  • Types: Ventricular fibrillation (VF), ventricular tachycardia (VT), atrial fibrillation, AV block
  • Pathophysiology: Electrical instability due to ischemic myocardium
  • Clinical Clues: Sudden cardiac arrest, palpitations, syncope, bradycardia
  • High Risk: Anterior MI and inferior MI (AV nodal ischemia)
  • Management:
    • VF/VT: Immediate defibrillation, amiodarone or lidocaine
    • Symptomatic bradycardia: Atropine, temporary pacing if needed
    • AF: Rate control, consider anticoagulation

Early (1–3 Days)

2. Early Pericarditis

  • Pathophysiology: Inflammatory response of pericardium over infarcted myocardium
  • Presentation: Sharp, pleuritic chest pain relieved by leaning forward; pericardial friction rub; diffuse ST elevation without reciprocal changes
  • Management: NSAIDs (ibuprofen 600-800 mg TID) ± colchicine; avoid anticoagulation if large effusion

Subacute (3–7 Days)

3. Papillary Muscle Rupture

  • Pathophysiology: Infarction → necrosis → rupture, especially of posteromedial muscle (RCA-dependent)
  • Clinical Clues: Acute severe mitral regurgitation, flash pulmonary edema, hypotension, new loud holosystolic murmur at apex radiating to axilla
  • Seen In: Inferior MI
  • Diagnosis: Echocardiography shows flail leaflet
  • Management: Emergency surgical repair; medical stabilization with afterload reduction, IABP

4. Interventricular Septal Rupture

  • Pathophysiology: Full-thickness necrosis of septum leads to left-to-right shunt
  • Clinical Clues: Sudden heart failure, cardiogenic shock, harsh holosystolic murmur at left sternal border (LSB), oxygen step-up in RV on right heart catheterization
  • Diagnosis: Echocardiography with color Doppler shows shunt
  • Management: Emergency surgical repair; stabilization with IABP, inotropes

5. Free Wall Rupture

  • Pathophysiology: Full-thickness LV rupture leads to hemopericardium → cardiac tamponade → pulseless electrical activity (PEA)
  • Clinical Clues: Sudden death, pulseless electrical activity, hypotension, distended neck veins, muffled heart sounds (Beck’s triad)
  • Risk Factors: Elderly, female, first MI, no prior infarct/scar, anterior MI
  • Diagnosis: Echocardiography (if time permits) shows pericardial effusion with tamponade
  • Management: Emergency pericardiocentesis and surgical repair (very high mortality)

Late (1–2 Weeks)

6. Mural Thrombus

  • Pathophysiology: Akinesis + endocardial damage → thrombus formation in LV (usually apical with anterior MI)
  • Clinical Clues: Often asymptomatic OR systemic embolism (stroke, limb ischemia)
  • Diagnosis: Echocardiography (TTE or TEE), cardiac MRI
  • Management: Anticoagulation (warfarin INR 2-3, or DOAC) for 3-6 months; repeat imaging to assess resolution

Chronic (2 Weeks to Months)

7. Left Ventricular Aneurysm

  • Pathophysiology: Scarred, thinned myocardium balloons outward during systole (usually anterior wall)
  • Clinical Clues: Persistent ST elevations on ECG (weeks after MI), HF symptoms, embolic strokes, ventricular arrhythmias, paradoxical precordial pulsation
  • Diagnosis: Echocardiography, cardiac MRI, ventriculography
  • Management: Medical therapy for HF; surgical aneurysmectomy if refractory HF or arrhythmias; anticoagulation for mural thrombus

8. Dressler Syndrome (Post-MI Syndrome)

  • Pathophysiology: Autoimmune pericarditis triggered by myocardial antigens (typically 2-10 weeks post-MI)
  • Clinical Clues: Fever, pleuritic chest pain, pericardial effusion, pleural effusion, elevated ESR/CRP
  • Diagnosis: Clinical diagnosis; ECG shows diffuse ST elevations; echocardiography shows pericardial effusion
  • Management:
    • NSAIDs (ibuprofen 600-800 mg TID) ± colchicine 0.5 mg daily
    • Avoid anticoagulation due to bleeding risk with effusion
    • Corticosteroids for refractory cases

Consults #

Cardiology

  • ALL patients with suspected or confirmed ACS (immediate)
  • STEMI: Activate cath lab for primary PCI
  • Risk stratification and timing of invasive strategy

Cardiac Surgery

  • Mechanical complications (papillary muscle rupture, VSD, free wall rupture)
  • Left main disease or complex 3-vessel disease requiring CABG
  • Failed PCI

Cardiac Rehabilitation

  • ALL post-MI patients (refer before discharge)

Patient Education #

Counseling (Lifestyle Modifications):

Smoking Cessation:

  • Strongest modifiable risk factor for recurrent MI and cardiovascular death
  • All patients should be counseled and offered pharmacotherapy (varenicline, bupropion, nicotine replacement)
  • Referral to smoking cessation programs

Diet:

  • Mediterranean Diet or DASH Diet (Dietary Approaches to Stop Hypertension)
  • Emphasize: fruits, vegetables, whole grains, lean proteins, fish, nuts, olive oil
  • Limit: saturated fats, trans fats, sodium (<2,300 mg/day), refined sugars, red meat
  • Target: LDL-C <70 mg/dL, ideally <55 mg/dL

Exercise:

  • At least 150 minutes/week of moderate-intensity aerobic activity (e.g., brisk walking) OR 75 minutes/week of vigorous-intensity activity
  • Resistance training 2 days/week
  • Cardiac rehabilitation strongly recommended for all post-MI patients

Weight Management:

  • Target BMI 18.5-24.9 kg/m²
  • Waist circumference: <40 inches (men), <35 inches (women)

Medication Adherence:

  • Crucial for secondary prevention
  • Address barriers: cost, side effects, complexity of regimen
  • Consider pill organizers, smartphone reminders

Alcohol:

  • If consumed, limit to ≤1 drink/day for women, ≤2 drinks/day for men
  • No alcohol recommended if history of alcohol abuse or cardiomyopathy

Erectile Dysfunction:

  • Common post-MI, often due to anxiety
  • Beta-blockers are a common cause
  • Important: Do NOT combine nitrates with sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) due to risk of profound hypotension
  • Safe to use PDE5 inhibitors if NOT on nitrates and >24 hours since last nitroglycerin use (48 hours for tadalafil)

Screening Recommendations (USPSTF):

Primary Prevention with Aspirin [16]

Ages 40-59 years:

  • Individualized decision (Grade C) for those with ≥10% 10-year cardiovascular disease (CVD) risk
  • Small net benefit; decision should consider bleeding risk and patient preference
  • Calculate risk using ACC/AHA Pooled Cohort Equations

Ages ≥60 years:

  • Do NOT initiate aspirin for primary prevention (Grade D)
  • Insufficient benefit; bleeding risk outweighs benefits

Note: These recommendations apply to PRIMARY prevention only. Patients with established CAD or prior MI should continue aspirin for SECONDARY prevention.

Primary Prevention with Statins [17]

Ages 40-75 years with ≥1 CVD risk factor AND 10-year CVD risk ≥10%:

  • Prescribe statin (Grade B)
  • CVD risk factors: dyslipidemia, diabetes, hypertension, smoking

Ages 40-75 years with ≥1 CVD risk factor AND 10-year CVD risk 7.5% to <10%:

  • Selectively offer statin (Grade C)
  • Smaller benefit; individualized decision

Ages ≥76 years:

  • Insufficient evidence to recommend for or against initiating statin (Grade I)

Note: All post-MI patients should be on high-intensity statin therapy regardless of age or baseline LDL for SECONDARY prevention.

Vaccines:

Influenza Vaccine:

  • Annual vaccination recommended for all patients with cardiovascular disease
  • Reduces cardiovascular events and mortality in CAD patients
  • Timing: Fall season (September-November in Northern Hemisphere)

Pneumococcal Vaccine:

  • Recommended for all patients with cardiovascular disease
  • PCV20 (Prevnar 20): Single dose, OR
  • PCV15 (Prevnar 15) followed by PPSV23 (Pneumovax 23) ≥1 year later
  • Protects against pneumonia, which increases cardiovascular risk

COVID-19 Vaccine:

  • Recommended for all patients with cardiovascular disease
  • Stay up-to-date with current CDC recommendations
  • Reduces severe illness and cardiovascular complications

Tdap (Tetanus-Diphtheria-Pertussis):

  • One-time dose if not previously received
  • Td or Tdap booster every 10 years

Follow-Up #

Short-Term Follow-Up (Post-Discharge)

Cardiology Visit:

  • Within 1-2 weeks post-discharge
  • Assess medication adherence, side effects
  • Review risk factor modification progress
  • Evaluate for complications

Laboratory Monitoring:

  • Lipid panel: 4-6 weeks after starting/adjusting statin therapy
    • Goal: LDL-C <70 mg/dL (ideally <55 mg/dL)
  • Renal function and electrolytes: If on ACE inhibitor, ARB, or aldosterone antagonist (check within 1-2 weeks, then periodically)
  • HbA1c: If diabetic (every 3-6 months)
  • Liver function tests: If on high-dose statin or if symptoms suggest hepatotoxicity

Blood Pressure:

  • Goal: <130/80 mmHg
  • Home BP monitoring encouraged

Cardiac Rehabilitation

Strongly Recommended for ALL Post-MI Patients:

  • Supervised exercise training program
  • Nutritional counseling
  • Psychosocial support
  • Risk factor modification education

Benefits:

  • Improved functional capacity
  • Reduced cardiovascular mortality (20-30% reduction)
  • Improved quality of life
  • Better medication adherence

Duration: Typically 36 sessions over 12-36 weeks

Barriers: Cost, transportation, availability

  • Consider home-based programs if facility-based not feasible

Depression Screening

Post-MI depression is common (15-30% of patients):

  • Screen using validated tools (PHQ-9)
  • Depression associated with worse outcomes and medication non-adherence
  • Treatment: SSRIs (sertraline preferred – safest in CVD), cognitive behavioral therapy
  • Avoid tricyclic antidepressants (proarrhythmic)

Long-Term Follow-Up

Every 3-6 months initially, then annually if stable:

  • Monitor for recurrent symptoms
  • Assess medication adherence and side effects
  • Review risk factor control (BP, lipids, glucose, weight)
  • Functional status and quality of life

Repeat Stress Testing:

  • NOT routinely recommended in asymptomatic patients
  • Consider if recurrent symptoms, significant change in functional status, or before returning to high-risk occupation

Repeat Echocardiography:

  • 3-6 months post-MI if initial EF reduced (<40%)
  • Annually if persistent LV dysfunction

Antiplatelet Therapy Review:

  • Reassess DAPT duration annually
  • Consider bleeding risk vs. ischemic risk
  • Transition to aspirin monotherapy after 12 months in most patients (unless high ischemic risk)

References #

  1. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. https://doi.org/10.1093/eurheartj/ehad191
  2. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. https://doi.org/10.1161/CIR.0000000000000617
  3. Chapman AR, Adamson PD, Shah ASV, et al. High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. Circulation. 2020;141(3):161-171. https://doi.org/10.1161/CIRCULATIONAHA.119.042960
  4. Sandoval Y, Apple FS, Mahler SA, et al. High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain. Circulation. 2022;146(8):569-581. https://doi.org/10.1161/CIRCULATIONAHA.122.059678
  5. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771-e862. https://doi.org/10.1161/CIR.0000000000001309
  6. Kereiakes DJ. Dual Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention: Time for a Change. J Soc Cardiovasc Angiogr Interv. 2025;4:102496. https://doi.org/10.1016/j.jscai.2024.102496
  7. Wenger NK. What US Cardiology Can Learn From the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Clin Cardiol. 2024;47(8):e24329. https://doi.org/10.1002/clc.24329
  8. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077
  9. Kim YG, Park DG, Moon SY, et al. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation. J Am Heart Assoc. 2023;12(5):e027824. https://doi.org/10.1161/JAHA.122.027824
  10. Lundbäck M, Venkateshvaran A, Henriksson P, Manca L, Bandaru P, Svedlund S. SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART. Lancet Reg Health Eur. 2024;45:101033. https://doi.org/10.1016/j.lanepe.2024.101033
  11. von Lewinski D, Kolesnik E, Aziz F, et al. Timing of SGLT2i initiation after acute myocardial infarction. Cardiovasc Diabetol. 2023;22:270. https://doi.org/10.1186/s12933-023-02000-5
  12. Xiong B, He L, Zhang A, Ling Z. Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes: an updated systematic review and meta-analysis. BMC Cardiovasc Disord. 2025;25(1):75. https://doi.org/10.1186/s12872-025-04992-2
  13. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. https://doi.org/10.1056/NEJMoa1912388
  14. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. https://doi.org/10.1056/NEJMoa2021372
  15. Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease. J Am Coll Cardiol. 2023;82(7):648-660. https://doi.org/10.1016/j.jacc.2023.05.055
  16. US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):1577-1584. https://doi.org/10.1001/jama.2022.4983
  17. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753. https://doi.org/10.1001/jama.2022.13044

#

Updated on December 10, 2025